tiprankstipranks
Biotest AG (DE:BIO)
XETRA:BIO

Biotest (BIO) Stock Price & Analysis

1 Followers

BIO Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€39.60 - €44.00
Previous Close€41.6
Volume0.00
Average Volume (3M)221.00
Market Cap
€1.38B
Enterprise Value€1.81B
Total Cash (Recent Filing)€136.60M
Total Debt (Recent Filing)€574.30M
Price to Earnings (P/E)9.3
Beta0.03
Jul 30, 2024
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.47
Shares Outstanding19,785,726
10 Day Avg. Volume10
30 Day Avg. Volume221
Standard Deviation0.07
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

BIO FAQ

What was Biotest AG’s price range in the past 12 months?
Biotest AG lowest stock price was €39.60 and its highest was €44.00 in the past 12 months.
    What is Biotest AG’s market cap?
    Currently, no data Available
    When is Biotest AG’s upcoming earnings report date?
    Biotest AG’s upcoming earnings report date is Jul 30, 2024 which is in 82 days.
      How were Biotest AG’s earnings last quarter?
      Biotest AG released its earnings results on May 07, 2024. The company reported €0.746 earnings per share for the quarter, beating the consensus estimate of N/A by €0.746.
        Is Biotest AG overvalued?
        According to Wall Street analysts Biotest AG’s price is currently same. Get more investment ideas with TipRanks Premium
          Does Biotest AG pay dividends?
          Biotest AG pays a Notavailable dividend of €0.04 which represents an annual dividend yield of N/A. See more information on Biotest AG dividends here
            What is Biotest AG’s EPS estimate?
            Biotest AG’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Biotest AG have?
            Biotest AG has 19,785,727 shares outstanding.
              What happened to Biotest AG’s price movement after its last earnings report?
              Biotest AG reported an EPS of €0.746 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Biotest AG?
                Currently, no hedge funds are holding shares in DE:BIO
                ---

                Biotest Stock Smart Score

                7
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                0.00%
                12-Months-Change

                Fundamentals

                Return on Equity
                40.25%
                Trailing 12-Months
                Asset Growth
                21.56%
                Trailing 12-Months

                Company Description

                Biotest AG

                Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Affimed
                Mainz Biomed B.V.
                Biotest
                Fusion Antibodies Plc
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis